Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) wit

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism Sign In New user? Click Here Subscribe Sign In New user? Click Here OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES more OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES OPINION NEWS REGIONS WORLD BUSINESS SPORTS ENTERTAINMENT LIFESTYLE THE SUNDAY TIMES SPECIAL FEATURES SPECIAL SECTIONS TMT NEWSWIRE Media OutReach Newswire PR Newswire GlobeNewswire Plentisoft FAST TIMES LEGAL ADVICE CAMPUS PRESS VIDEOS EXPATS & DIPLOMATS PHOTOS BUSINESS FORUM PODCASTS RESOURCES WEATHER MARKET OVERVIEW The Manila Times 500 EXAM RESULTS TMT DIGITAL EDITION TMT CSI TMT 127TH ANNIVERSARY QUIZZES GAMES TMT Newswire GlobeNewswire Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism By GlobeNewswire June 6, 2026 Resize Small Medium Large STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676 , a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.